Physician profile
Ikechi C Nnawuchi
NPI 1598798662
$623,579.88
in general payments reported to CMS, 2019-2025
16 companies · $98K in 2025
The $98K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $35K · 2021: $102K · 2022: $123K · 2023: $84K · 2024: $64K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $193K · Consulting Fee: $19K · Travel and Lodging: $17K · Food and Beverage: $17K · Education: $65.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $193,095.00 |
| Consulting Fee | $19,435.50 |
| Travel and Lodging | $17,169.88 |
| Food and Beverage | $16,539.25 |
| Education | $65.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $410,713.42 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $90,604.35 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $68,308.41 | 2021-2025 | |
| Allergan, INC. | $23,498.34 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15,223.95 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $4,148.67 | 2019-2022 | |
| Corium, LLC | $2,253.23 | 2022-2023 | Azstarys |
| Lundbeck LLC | $1,961.02 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $1,691.24 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $1,417.13 | 2020-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,395.00 | 2020-2025 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $1,141.80 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $913.94 | 2024-2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $148.92 | 2025 | Invega Sustenna |
| Indivior INC. | $146.80 | 2022-2025 | Sublocade |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikechi Nnawuchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.